[HTML][HTML] Integrative Analysis of Multi-Omics Data to Identify Deregulated Molecular Pathways and Druggable Targets in Chronic Lymphocytic Leukemia
D Mavridou, K Psatha, M Aivaliotis - Journal of Personalized Medicine, 2024 - mdpi.com
Chronic Lymphocytic Leukemia (CLL) is the most common B-cell malignancy in the Western
world, characterized by frequent relapses despite temporary remissions. Our study …
world, characterized by frequent relapses despite temporary remissions. Our study …
Bosutinib for the Treatment of CML—Using it Safely: a Podcast
JH Lipton, JE Cortes - Targeted Oncology, 2025 - Springer
Bosutinib is a second-generation tyrosine kinase inhibitor (TKI) approved for use in patients
with newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase (CP) chronic …
with newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase (CP) chronic …
A lower initial dose of bosutinib for patients with chronic myeloid leukemia patients resistant and/or intolerant to prior therapy: a single-arm, multicenter, phase 2 trial …
H Ureshino, N Takahashi, T Ikezoe, Y Kameoka… - International Journal of …, 2024 - Springer
Although bosutinib is generally safe and effective, drug-related toxicities (DRTs) such as
diarrhea or increased transaminase levels often lead to treatment discontinuation. To clarify …
diarrhea or increased transaminase levels often lead to treatment discontinuation. To clarify …
Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring
E Jabbour, H Kantarjian - American journal of hematology, 2024 - Wiley Online Library
Disease overview Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with an
annual incidence of two cases/100 000. It accounts for approximately 15% of newly …
annual incidence of two cases/100 000. It accounts for approximately 15% of newly …
Bosutinib Treatment of Chronic Myeloid Leukemia in Lombardy
A Iurlo, C Bucelli, T Intermesoli, C Elena, M D'Adda… - Acta …, 2024 - karger.com
Introduction Up to 30% of CML patients will require a therapeutic change during follow‐up,
due to intolerance and/or resistance to first‐line TKI approach. In this context, bosutinib …
due to intolerance and/or resistance to first‐line TKI approach. In this context, bosutinib …